Pharma BD Deal Intelligence
Merck's $10.8B all-cash buy of Prometheus locked up tulisokibart (MK-7240), an anti-TL1A antibody that posted 26% clinical remission versus 1% placebo in Phase 2 ulcerative colitis. Merck has since pushed it into Phase 3 for UC and Crohn's plus three more inflammatory-disease trials, though the pivotal UC readout isn't due until November 2026.
Merck's $11B Prometheus acquisition brings not just an IBD drug but a precision medicine companion diagnostic platform — a unique opportunity to establish…
Merck initiated three Phase 2b trials of tulisokibart (MK-7240) in hidradenitis suppurativa, radiographic axial spondyloarthritis, and rheumatoid arthritis;…
Merck today announced that it has entered into a definitive agreement to acquire Prometheus Biosciences, Inc. for $200.00 per share in cash for a total equity…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Merck acquired Prometheus Biosciences for approximately $10.8 billion ($200.00 per share in cash; announced April 16, 2023, completed June 16, 2023), gaining PRA023 — now branded tulisokibart (MK-7240), a humanized anti-TL1A monoclonal antibody — to strengthen its immunology pipeline. The lead Phase 2 ARTEMIS-UC ulcerative colitis study (published in NEJM, September 26, 2024) showed clinical remission of 26% with tulisokibart versus 1% with placebo at week 12. Post-close, Merck advanced the asset into a two-study Phase 3 IBD program — ATLAS-UC in ulcerative colitis and ARES-CD in Crohn's disease (UC preliminary readout expected November 2026) — and on October 6, 2025 expanded development into three additional immune-mediated inflammatory diseases (hidradenitis suppurativa, radiographic axial spondyloarthritis, and rheumatoid arthritis) via new Phase 2b trials.
Tulisokibart (MK-7240) is a Phase II anti-TL1A monoclonal antibody for moderate-to-severe Crohn's disease (CD), entering a crowded, multi-mechanism market. TNF inhibitors (legacy standard): infliximab (Remicade, Janssen; biosimilars Inflectra, Renflexis, Avsola), adalimumab (Humira, AbbVie; biosimilars) and certolizumab pegol (Cimzia, UCB) still anchor first-line biologic use. Anti-alpha4beta7 integrin: vedolizumab (Entyvio, Takeda) is FDA-approved in CD and generated ~$7.9B global FY2023 (Takeda FY2023 annual report). IL-12/23 and IL-23p19: ustekinumab (Stelara, J&J; biosimilars post-2025), risankizumab (Skyrizi, AbbVie; FDA-approved in CD June 2022), and mirikizumab (Omvoh, Lilly; CD approval Jan 2025) are the fastest-growing MOA class. JAK1 inhibitors: upadacitinib (Rinvoq, AbbVie) is FDA-approved for CD after TNF failure (May 2023). Other anti-TL1A (direct MOA competition): duvakitug (TEV-48574, Teva/Sanofi) is in Phase III and the most direct franchise threat; afimkibart (RO7790121, Roche) is Phase II. Pipeline: etrasimod (S1P) failed in CD. For a commercial lead, the TL1A class faces a two-horse race (Merck vs Teva/Sanofi) into a market already dominated by Skyrizi's rapid uptake and Entyvio's safety incumbency.
Tulisokibart (MK-7240, anti-TL1A) has no disclosed rheumatoid arthritis (RA) program; this landscape frames the highly saturated RA market it would enter if expanded. TNF inhibitors: adalimumab (Humira, AbbVie; 10+ biosimilars including Amjevita, Cyltezo, Hadlima), etanercept (Enbrel, Amgen), infliximab (Remicade, Janssen; biosimilars), certolizumab pegol (Cimzia, UCB), and golimumab (Simponi, Janssen) are all FDA-approved and remain the volume backbone. IL-6/IL-6R inhibitors: tocilizumab (Actemra, Roche; biosimilar Tyenne), sarilumab (Kevzara, Regeneron/Sanofi). T-cell co-stimulation: abatacept (Orencia, BMS). Anti-CD20: rituximab (Rituxan, Roche/Biogen; biosimilars Ruxience, Truxima). JAK inhibitors: tofacitinib (Xeljanz, Pfizer), baricitinib (Olumiant, Lilly), and upadacitinib (Rinvoq, AbbVie) are now post-TNF standard, though a 2021 FDA boxed warning restricted first-line JAK use. Conventional DMARDs (different MOA): methotrexate and hydroxychloroquine remain first-line. For a commercial lead, the RA market is effectively saturated with biosimilar-driven pricing pressure on Humira and an established JAK second-line; TL1A has no RA biology rationale and any franchise threat from Merck's asset in RA is speculative and low.
Tulisokibart (MK-7240, anti-TL1A) is not in active registrational development for hidradenitis suppurativa (HS); this landscape frames the approved and late-stage HS competitor set the asset would face if indication-expanded. TNF inhibitors: adalimumab (Humira, AbbVie; biosimilars) has been the only FDA-approved biologic in HS since 2015 and remains the share anchor; infliximab (Remicade) is used off-label. IL-17 inhibitors: secukinumab (Cosentyx, Novartis) received FDA approval for moderate-to-severe HS in October 2023, and bimekizumab (Bimzelx, UCB) received FDA approval for HS in October 2024 — both are the most direct franchise threats to Humira in HS. IL-1 family: spesolimab (Spevigo, Boehringer Ingelheim; anti-IL-36R) is approved in generalized pustular psoriasis and in late-stage HS trials. JAK inhibitors: povorcitinib (INCB054707, Incyte) is Phase III in HS. IL-17A/F and other: sonelokinab (ALX148-adjacent agents) are earlier-phase. For a commercial lead, the HS market is rapidly transitioning from Humira monopoly to an IL-17 duopoly (Cosentyx, Bimzelx), and any TL1A entrant would need mechanism-specific biomarker rationale to compete — TL1A has no established HS biology and franchise threat is low.
Tulisokibart (MK-7240) is a Phase II anti-TL1A monoclonal antibody whose lead indications are ulcerative colitis and Crohn's disease; it has not reported registrational data in axial spondyloarthritis (axSpA), so the competitive frame here is the established biologic/tsDMARD market it would need to disrupt if expanded. TNF inhibitors (standard of care): adalimumab (Humira, AbbVie; biosimilars), etanercept (Enbrel, Amgen), certolizumab pegol (Cimzia, UCB), infliximab (Remicade, Janssen; biosimilars), and golimumab (Simponi, Janssen) are all FDA-approved in ankylosing spondylitis and/or non-radiographic axSpA and represent the primary share anchor. IL-17 inhibitors: secukinumab (Cosentyx, Novartis) and ixekizumab (Taltz, Lilly) are FDA-approved across axSpA and are the most clinically differentiated biologics, with bimekizumab (Bimzelx, UCB) also now approved in axSpA. JAK inhibitors: tofacitinib (Xeljanz, Pfizer) and upadacitinib (Rinvoq, AbbVie) are approved for AS and nr-axSpA. IL-23p19: risankizumab (Skyrizi, AbbVie) failed in axSpA, and the MOA class does not dominate. For a commercial lead, TL1A has no axSpA signal yet — franchise threat is speculative and any future axSpA positioning would have to displace IL-17 and JAK second-line options, not just TNFs.
Tulisokibart (MK-7240) is a Phase II/III anti-TL1A monoclonal antibody for moderate-to-severe ulcerative colitis (UC), entering a market anchored by multiple MOA classes. TNF inhibitors: infliximab (Remicade, Janssen; biosimilars), adalimumab (Humira, AbbVie; biosimilars), golimumab (Simponi, Janssen) are the legacy backbone. Anti-alpha4beta7 integrin: vedolizumab (Entyvio, Takeda) is FDA-approved in UC and recorded ~$7.9B global FY2023 revenue (Takeda FY2023 annual report). IL-12/23 and IL-23p19: ustekinumab (Stelara, J&J), mirikizumab (Omvoh, Lilly; FDA-approved UC Oct 2023), and risankizumab (Skyrizi, AbbVie; FDA-approved UC June 2024) are fast-growing. JAK inhibitors: tofacitinib (Xeljanz, Pfizer) and upadacitinib (Rinvoq, AbbVie; FDA-approved UC March 2022). S1P modulators: ozanimod (Zeposia, BMS) and etrasimod (Velsipity, Pfizer) are oral options. Anti-TL1A (direct MOA competition): duvakitug (TEV-48574, Teva/Sanofi) is in Phase III UC and the closest franchise threat; afimkibart (RO7790121, Roche) is Phase II. For a commercial lead, TL1A faces a head-to-head Merck vs Teva/Sanofi race into a market already undergoing displacement from TNFs to IL-23p19 and oral small molecules. TL1A differentiation depends on the Prometheus biomarker (TL1A expression signature) to justify a precision positioning.
ARTEMIS-UC showed exceptional efficacy driving the $10.8B acquisition. Part of Merck & Co. Inc.'s $10.8B deal to acquire Prometheus Biosciences Inc..
Merck & Co. Inc. completed its acquisition of Prometheus Biosciences Inc. for $10.8B.
Tulisokibart advanced to Phase 3 with maintained efficacy at week 50. Part of Merck & Co. Inc.'s $10.8B deal to acquire Prometheus Biosciences Inc..
Phase 2b initiated in RA, broadening anti-TL1A platform beyond IBD. Part of Merck & Co. Inc.'s $10.8B deal to acquire Prometheus Biosciences Inc..
Beyond the ATLAS-UC and ARES-CD Phase 3 IBD program, Merck initiated Phase 2b trials in hidradenitis suppurativa, radiographic axial spondyloarthritis, and rheumatoid arthritis, broadening the acquired anti-TL1A asset beyond inflammatory bowel disease.
Outstanding Phase 2 data. Pre-revenue but multibillion-dollar peak sales potential.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Prometheus Biosciences Inc. (this deal) | 2023 | $10.8B | 77 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2023 deals · Merck & Co. Inc. deals · Dermatology deals